Post-earnings recap
Reported
Tue, Jul 28, 2026
EPS actual
$0.54
EPS est.
$0.45
EPS surprise
+19.47%
1-day move
+10.90%
Repligen Corporation reported better-than-expected earnings per share, which contributed to a strong stock reaction, rising by 10.9%. However, there was no revenue figure provided, leaving some uncertainty about overall performance. Investors may be encouraged by the EPS beat, indicating potential operational strength.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.54 | $0.46 | +19.47% |
| Revenue | — | $207M | — |
No transcript is on record, and the analysis is based on numerical results only.
Repligen Corporation (RGEN) is a key player in the health care sector, focusing on life sciences tools and services. The company specializes in providing products and technologies that support the development and manufacturing of biologic drugs, which are increasingly important in the pharmaceutical industry.
Last quarter
In Q1-2026, Repligen reported an EPS of $0.48, exceeding expectations by 25%. The stock responded positively, gaining over 6% the following day.
EPS beat streak
4Q
EPS beat rate
88%
Avg EPS surprise
+13.49%
Avg 1-day reaction
+3.37%
Analysts are generally optimistic about Repligen's upcoming earnings, with expectations for continued growth in both EPS and revenue.
Bull case
If Repligen meets or exceeds the consensus EPS and revenue estimates, it could indicate strong demand for its products and lead to a positive market reaction.
Bear case
Conversely, if the company fails to meet expectations, it could raise concerns about its growth prospects and lead to a decline in stock price.
Key metrics to watch
EPS
0.46Earnings per share is a critical indicator of profitability and reflects the company's ability to generate profit for its shareholders.
Revenue
207MRevenue figures provide insight into the company's sales performance and overall market demand for its products.
The print will turn on these.
Q1
Will Repligen's EPS exceed the consensus estimate of $0.46?
A beat on EPS could signal strong operational performance and boost investor confidence.
Q2
What revenue growth will Repligen report relative to the consensus of $207M?
Revenue growth is crucial for assessing the company's market position and demand for its products.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±3.5%
Why consensus could be wrong
The consensus may underestimate Repligen's ability to capitalize on increasing demand in the biologics market, especially given its recent product innovations.
Supporting evidence
Repligen has consistently beaten EPS estimates in the past, suggesting stronger operational performance than projected.
The options market is pricing a smaller move than historical averages, indicating potential for a larger reaction.
Recent trends in the life sciences sector indicate a growing demand for biologic manufacturing tools, which Repligen specializes in.
Key risk
If the company reports significant new contracts or partnerships, it could shift market sentiment dramatically.
Pre-commit to what would confirm each case.
The market is focused on Repligen's ability to maintain growth in a competitive environment, making these metrics critical.
Bull confirmed if
An EPS of $0.48 or higher with revenue exceeding $210M would confirm the bull case.
Bear confirmed if
An EPS below $0.41 or revenue below $205M would confirm the bear case.
What the market is pricing for the move.
Implied Move
±4.1%
Historical Avg
±5.7%
The options market is pricing in a modest move around the earnings announcement, suggesting uncertainty about the results.
Options are pricing ±4.1% while RGEN has averaged ±5.7% over the last 8 prints — setup is pricing cheap.
ATM IV
0.6%
30d HV
59.6%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$3.5M
18,481 sh
1 insider
Net
$3.5M
Net selling
Most Active Insiders· 4 open-market trades
$3.5M
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
106.22%
of float
Insider
4.66%
of float
Holders
659
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
5,384,938 sh · $900.5M
9.54%
-10.2%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Repligen beats expectations, history suggests the stock could rise by about 3.95%, confirming strong demand.
In line / cautious
If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.
Miss
If the company misses estimates, history suggests a potential decline of around 4.72%, raising concerns about future growth.
The lines on the call that would change the story.
Recent Transactions
Sep 24, 2026 · @ $190.00
8,404 sh
$1.6M
Sep 24, 2026 · @ $190.00
4,542 sh
$862,980.00
Oct 5, 2026 · @ $190.00
4,202 sh
$798,380.00
Oct 5, 2026 · @ $178.75
1,333 sh
$238,273.75
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
FMR, LLC
3,326,690 sh · $556.3M
5.89%
15.2%
United Capital Financial Advisors, LLC
2,790,650 sh · $466.7M
4.94%
0.6%
Vanguard Capital Management LLC
2,411,171 sh · $403.2M
4.27%
0.6%
Vanguard Portfolio Management LLC
2,312,825 sh · $386.8M
4.10%
0.3%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.